210 related articles for article (PubMed ID: 19229530)
1. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
Kuoppamäki M; Korpela K; Marttila R; Kaasinen V; Hartikainen P; Lyytinen J; Kaakkola S; Hänninen J; Löyttyniemi E; Kailajärvi M; Ruokoniemi P; Ellmén J
Eur J Clin Pharmacol; 2009 May; 65(5):443-55. PubMed ID: 19229530
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
Rouru J; Gordin A; Huupponen R; Huhtala S; Savontaus E; Korpela K; Reinikainen K; Scheinin M
Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
[TBL] [Abstract][Full Text] [Related]
3. The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations.
Ingman K; Naukkarinen T; Vahteristo M; Korpela I; Kuoppamäki M; Ellmén J
Eur J Clin Pharmacol; 2012 Mar; 68(3):281-9. PubMed ID: 21927836
[TBL] [Abstract][Full Text] [Related]
4. Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers.
Nyholm D; Ehrnebo M; Lewander T; Trolin CG; Bäckström T; Panagiotidis G; Spira J; Nyström C; Aquilonius SM
Acta Neurol Scand; 2013 Feb; 127(2):124-32. PubMed ID: 22762460
[TBL] [Abstract][Full Text] [Related]
5. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
[TBL] [Abstract][Full Text] [Related]
6. Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.
Kuoppamäki M; Sauramo A; Korpela K; Vahteristo M; Kailajärvi M; Lehtinen T; Ellmén J
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):756-60. PubMed ID: 20979935
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)).
Hsu A; Yao HM; Gupta S; Modi NB
J Clin Pharmacol; 2015 Sep; 55(9):995-1003. PubMed ID: 25855267
[TBL] [Abstract][Full Text] [Related]
8. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
9. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
Heikkinen H; Varhe A; Laine T; Puttonen J; Kela M; Kaakkola S; Reinikainen K
Br J Clin Pharmacol; 2002 Oct; 54(4):363-71. PubMed ID: 12392583
[TBL] [Abstract][Full Text] [Related]
10. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A
J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888
[TBL] [Abstract][Full Text] [Related]
11. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
Paija O; Laine K; Kultalahti ER; Leinonen M; Huupponen R; Gordin A; Reinikainen K
Clin Neuropharmacol; 2005; 28(3):115-9. PubMed ID: 15965309
[TBL] [Abstract][Full Text] [Related]
12. Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
Senek M; Nielsen EI; Nyholm D
Mov Disord; 2017 Feb; 32(2):283-286. PubMed ID: 27987231
[TBL] [Abstract][Full Text] [Related]
13. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.
Keränen T; Gordin A; Harjola VP; Karlsson M; Korpela K; Pentikäinen PJ; Rita H; Seppälä L; Wikberg T
Clin Neuropharmacol; 1993 Apr; 16(2):145-56. PubMed ID: 8477410
[TBL] [Abstract][Full Text] [Related]
14. Levodopa/carbidopa/entacapone (Stalevo).
Hauser RA
Neurology; 2004 Jan; 62(1 Suppl 1):S64-71. PubMed ID: 14718682
[TBL] [Abstract][Full Text] [Related]
15. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
Lew MF; Somogyi M; McCague K; Welsh M;
Int J Neurosci; 2011 Nov; 121(11):605-13. PubMed ID: 21843110
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
Müller T
Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
[TBL] [Abstract][Full Text] [Related]
18. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
Delea TE; Thomas SK; Hagiwara M; Mancione L
Curr Med Res Opin; 2010 Jul; 26(7):1543-52. PubMed ID: 20429819
[TBL] [Abstract][Full Text] [Related]
19. Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
Othman AA; Rosebraugh M; Chatamra K; Locke C; Dutta S
J Parkinsons Dis; 2017; 7(2):275-278. PubMed ID: 28211816
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
Vaz-da-Silva M; Loureiro AI; Nunes T; Lopes C; Rocha J; Machado R; Costa R; Torrão L; Falcão A; Wright L; Almeida L; Soares-da-Silva P
Drugs R D; 2008; 9(6):435-46. PubMed ID: 18989992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]